Navigation Links
Imagentix Offers Extension of Warrants
Date:10/23/2007

Warrant Holders to Pay $.05 to Extend

Call Provision to be Changed

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that its Board of Directors have approved the extending of several series of warrants that are scheduled to expire on October 23, 2007. The majority of these warrants have an exercise price from $1.00 to $2.00

Warrant holders will have the right to have their warrants extended until October 23, 2010 provided they pay to the Company $.05 per warrant no later than November 30, 2007. Those who elect to extend shall have the $.05 payment deducted from their exercise price. In addition, the Company will now have the right to call any series of warrants if the stock should trade at a 20% premium to the exercise price for 10 business days.

Commenting on the extension, Mr. William Spencer, President of Imagentix said, "We have decided to give our warrant holders, who are mostly long term supporters of the Company, the opportunity to extend their warrants if they should choose. By changing the call provision it will allow the Company to call warrants as the stock price increases if the Company needs additional capital to expand branding of its retail products."

About Imagenetix

Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marked globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit, http://www.imagenetix.net.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Roche offers HIV drug expertise to poor nations
5. Magnesium sulfate offers no help in migraine treatment
6. Drug Offers Hope for Alzheimers disease
7. Drug Firm Offers to Donate Smallpox Vaccine
8. fMRI Offers Insight Into An Infants Brain
9. Gel Offers A More Targeted Approach
10. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
11. Surgery Offers Better Treatment For Third Degree Piles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... , ... Coast Dental has a new way to help parents keep their ... dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, February 19 from ... at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will have healthy snacks, ...
(Date:2/8/2016)... Dallas, Texas (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous ... family members and significant others that they are loved. This year, for more than ... much they cost - just won't be enough to remind them of the lives they’ve ...
(Date:2/8/2016)... ... 2016 , ... Brenton Engineering , powered by Pro ... wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new solution ... or fully-automatic case packing with a small footprint, rugged, highly flexible, and cost-effective ...
(Date:2/8/2016)... ... 2016 , ... Tingley Rubber Corporation , a leading ... range of unique and advantaged protective solutions to a growing and dynamic ... customer service and marketing support. A new distribution center in Brampton, Ontario will ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell ... selected the latest beneficiary of their ongoing community enrichment program. The current campaign ... area schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology: